Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion

Addressing Issues With Endocrine Treatment in Metastatic Disease

Patient Cases

Patient Case 1

Patient Case 1 (cont)

What Is the Preferred Treatment Option for This Patient?

Is This Patient a Candidate for Chemotherapy?

Treatment Selection for Case Patient: Rationale

BOLERO-2 Trial: PFS by Central Assessment

PALOMA-3: PFS in Intent-To-Treat Population

Tolerability Profiles to Consider With Combination Approaches

Other Considerations With CDK4/6 Inhibitors

Managing Neutropenia Associated With CDK4/6 Inhibitors

Guideline Recommendations for ER-Positive/HER2-Negative MBC

Patient Case 2

Patient Case 2 (cont)

QTc Monitoring and CDK4/6 Inhibitors

What Is the Preferred Treatment Option for This Patient?

Patient Case: Rationale for Treatment Choices

The Choice to Use ET Monotherapy or ET in Combination With Another Agent

Patient Considerations

Drug Interactions With CDK4/6 Inhibitors

Concluding Remarks

Concluding Remarks (cont)